Graziana Lomastro

🔍 How can shared decision-making lead to better osteoporosis care? Clare Carroll, Global Integrated Insights Lead at UCB, highlights why understanding the lived experience of patients and the goals of medical professionals is key to closing care gaps. We’re at #FFN2025 to discuss how shared decision-making can lead to better, more personalized outcomes for people living with osteoporosis. This post is targeted at healthcare professionals. #SharedDecisionMaking #Osteoporosis #BoneHealth #FFN2025 #FragilityFractures #FracturePrevention

86

1 commento

We are leveraging our deep expertise in drug discovery and disease biology to research potential treatments for pulmonary fibrosis and other pulmonology diseases with high unmet needs. We look forward to participating at the European Respiratory Society Annual Congress where we’ll be presenting data that enhance our understanding of the patient experience in progressive pulmonary fibrosis (PPF) and the latest from our clinical program in idiopathic pulmonary fibrosis (IPF). Learn more about our work in pulmonology: https://bit.ly/46qrnvO #ERSCongress #OneBMS

130

4 commenti

With the EU #HTA regulation transforming how innovation reaches patients, companies must rethink strategies to stay ahead. From #PICO landscaping to early HTA integration, success demands collaboration and the right expertise. Hear from Cencora experts Herbert Altmann, Vice President of Market Access and Healthcare Consulting Europe, and Ruairi O’Donnell, EU HTA Lead, as they share actionable strategies to bridge gaps and thrive in this transformative regulatory landscape. 👉 Dive into the full conversation here: https://lnkd.in/ecZ26mDp

49

In a newly released case study, Medpace experts explore a Phase III registrational trial for a new class of antibiotic for the treatment of uncomplicated urinary tract infections. Download the case study to discover strategies for rapid site activation, streamlined trial operations, and minimizing patient and site burden—key factors in achieving a seamless and successful trial: https://lnkd.in/gfs7hvgh

49

1 commento

France’s Early Access system provides a vital route for patients to access innovative therapies ahead of market authorisation, but navigating its complexities requires precision and strategy. Watch nathalie CAIZERGUES, Medical Affairs Director, Europe, at the Clinigen Insights Virtual Week, as she breaks down: • Core requirements of France’s Early Access framework • How to handle exceptions and edge cases with confidence • Proven strategies for smooth and compliant implementation Watch the full session here https://lnkd.in/et6Gg6bP #EarlyAccess #MarketAccess #RegulatoryAffairs #ClinigenInsights #MAP #Pharma #HTA #France

41

Understanding the use and protection of your health data is crucial. At Roche, we provide full transparency on where data resides and offer flexible storage options, including on-premise and cloud-based solutions to healthcare organizations. Our approach complies with regional and international data protection standards and regulations. Learn more about how Roche manages data storage and residency: https://spkl.io/6048AO3Z0 #DigitalTrust #DataResidency #CloudSecurity #OnPremise #DataProtection #HealthcareIT #Roche #navify

118

Artificial intelligence is no longer a buzzword in life sciences—it’s a business imperative. In IQVIA’s 2025 survey of over 100 senior commercial leaders, one message came through loud and clear: AI is moving from pilot projects to core strategy. Download the full white paper to explore the data, insights, and leadership recommendations: https://lnkd.in/dp5qYf8R

62